EUVIMEDEUVIMED entdecken
Crossref

Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding

Wei Deng, HaiShan Li, YaYa Zhang, YueWei Lin, ChiWei Chen, JunChun Chen, YanBo Huang, Yi Zhou, YongChao Tang, JinYong Ding, Kai Yuan, LiangLiang Xu und 2 weitere

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Wei Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of…. Hauptthemen laut MEDLINE: Bone Resorption, Bone Density Conservation Agents, Bone Diseases, Metabolic, Osteoporosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Osteoporosis, a systemic metabolic bone disease, is often caused by the disruption of dynamic equilibrium between osteoclasts and osteoblasts. Overactive bone resorption, in which osteoclasts play a major role, is one of the most common and major causes of osteoporosis. Less costly and more effective drug treatments for this disease are needed. Based on the combination of molecular docking techniques and in vitro cell assays, this study aimed to explore the mechanism by which Isoliensinine (ILS) protects the bone loss by inhibiting osteoclast differentiation. METHODS: A virtual docking model based on molecular docking technology was used to investigate the interactions between ILS and the Receptor Activator of Nuclear Kappa-B (RANK)/Receptor Activator of Nuclear Kappa-B Ligand (RANKL).In this study, we determined the effective dose of action of ILS to inhibit osteoclast differentiation in vitro and, using bone resorption experiments, RT-CPR and Western Blot investigated the effects of ILS on bone resorption function and normal expression of osteoclast-associated genes and proteins, and validated potential mechanistic pathways. In vivo experiments revealed that ILS could inhibit bone loss through Micro-CT results. Finally, the molecular interaction between ILS and RANK/RANKL was investigated using biomolecular interaction experiments to verify the correctness and accuracy of the computational results. RESULTS: ILS binds to RANK and RANKL proteins, respectively, through virtual molecular docking. The Surface Plasmon Resonance (SPR) experiment results revealed that phosphorylated JNK, ERK, P38, and P65 expression was significantly downregulated when ILS were targeted to inhibit RANKL/RANK binding. At the same time, the expression of IKB-a was significantly increased under the stimulation of ILS, which rescued the degradation of IKB-a. ILS can significantly inhibit the levels of Reactive Oxygen Species (ROS) and Ca2 + concentration in vitro. Finally, the results of Micro-CT showed that ILS can significantly inhibit bone loss in vivo, indicating that ILS has a potential role in the treatment of osteoporosis. CONCLUSION: ILS inhibits osteoclast differentiation and bone loss by preventing the normal binding of RANKL/RANK, affecting downstream signaling pathways, including MAPK.NF-KB, ROS, Ca2+, genes, and proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone ResorptionBone Density Conservation AgentsBone Diseases, MetabolicOsteoporosisHumansReactive Oxygen SpeciesMolecular Docking SimulationCell DifferentiationOsteoclastsNF-kappa BRANK LigandOsteogenesisIsoquinolines

Stichwörter der Autor:innen

Ca(2+)IsoliensinineOsteoclastogenesisOsteoporosisROSSPR

Substanzen

Reactive Oxygen SpeciesNF-kappa BBone Density Conservation AgentsRANK LigandisoliensinineIsoquinolines

Autor:innen und Institutionen

  • No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Gua…
  • The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China.
  • Guangxi University of Chinese Medicine, No. 179, Mingxiu East Road, Nanning City, Guangxi Province 530200, China.
  • Guangxi Medical University, No. 22, Shuangyong Road, Qingxiu District, Nanning City, Guangxi Province 530021, China.

Zitieren

APA

Deng, W., Li, H., Zhang, Y., Lin, Y., Chen, C., Chen, J., Huang, Y., Zhou, Y., Tang, Y., Ding, J., Yuan, K., Xu, L., Li, Y., & Zhang, S. (2023). Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115463

Vancouver

Deng W, Li H, Zhang Y, Lin Y, Chen C, Chen J, et al. Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115463

BibTeX
@article{Deng2023,
  author = {Deng, Wei and Li, HaiShan and Zhang, YaYa and Lin, YueWei and Chen, ChiWei and Chen, JunChun and Huang, YanBo and Zhou, Yi and Tang, YongChao and Ding, JinYong and Yuan, Kai and Xu, LiangLiang and Li, YongXian and Zhang, ShunCong},
  title = {Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115463}
}
Kostenlos starten →